ARDELYX, INC. — Form 10-Q

Ardelyx amended its Commercial Supply Agreement with Catalent Pharma Solutions (effective May 11, 2026) to add new product strengths for Ibsrela® (50 mg) and Xphozah® (20 mg and 30 mg), establish separate commencement dates per product brand, and extend the term to 5 years from the last product's commencement date with automatic 2-year renewals thereafter. Simultaneously, it amended its Manufacturing Services Agreement with Patheon Pharmaceuticals (effective May 15, 2026) to clarify packaging, labeling, and serialization services when finished packaged product is ordered, add definitions for bulk and finished packaged products, and incorporate new pricing for specified configurations. Specific financial terms, maintenance fees, and pricing schedules are redacted [***].